INDP

Indaptus Therapeutics, Inc. Common Stock

3.32

USD

+0.16

+5.06%

Nov 06, 15:59 UTC -5

Closed

After-Market

3.26

-0.06

-1.81%

Indaptus Therapeutics, Inc. Common Stock (INDP) Earnings

INDP Earnings Reports

Positive Surprise Ratio

INDP beat 23 of 40 last estimates.

57%

Next Report

Tomorrow

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$1.48

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q3 25 (Revenue/ EPS)

-50.34%

Indaptus Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 11, 2026, INDP reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -1.60 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q3 26, 3 analysts forecast an EPS of -1.48 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

FAQ

What were Indaptus Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Indaptus Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Indaptus Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Indaptus Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for Indaptus Therapeutics, Inc. Common Stock's next earnings report?

Based on 3 analysts, Indaptus Therapeutics, Inc. Common Stock is expected to report EPS of -$1.48 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.